New combo therapy for lymphoma shows promise in early trial

NCT ID NCT01846390

First seen Apr 01, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This early-phase study tested a new combination of drugs (romidepsin plus standard chemotherapy) in 21 patients with peripheral T-cell or diffuse large B-cell lymphoma. The main goal was to find the safest dose and understand side effects. Researchers hope this combo might work better than current treatments, but more studies are needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Regional Health Authority B, Zone 2

    Saint John, New Brunswick, E2L 4L2, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2, Canada

  • Univ. Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.